Biogen Idec extends and defends bid against Facet's claim of higher value
This article was originally published in Scrip
Biogen Idec has extended its hostile bid for Facet Biotech by two months after the original offer expired on October 19th. By close of trading on October 15th, fewer than 1% of Facet's shareholders had tendered their shares, Biogen Idec revealed. Facet has reiterated its recommendation that shareholders reject the bid, the terms of which remain unchanged. Biogen Idec's extended tender offer closes on December 16th.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.